Publication of List of Manufacturers Revoked from Licensing for the Manufacture of Therapeutic Goods - NSW Deptartment of Primary Industries Environmental Laboratory

Overview

The Therapeutic Goods Act 1989 (TGA) was enacted to regulate the supply of therapeutic goods in Australia, ensuring their safety, quality, and efficacy. The Act provides a comprehensive framework for the control of therapeutic goods, including medicines, medical devices, and blood and blood components, through licensing and registration processes. The 1989 Act was introduced to address the need for a unified regulatory system that would protect public health by maintaining high standards for therapeutic goods available in the Australian market. The TGA is administered by the Therapeutic Goods Administration (TGA), an agency of the Australian Government's Department of Health. The policy objective of the Act is to safeguard the health and safety of the Australian community by controlling the supply of therapeutic goods and ensuring that only products meeting the required standards are available for use. This revocation of a manufacturer's licence under the Act exemplifies the TGA's role in enforcing compliance with these standards and maintaining the integrity of the therapeutic goods market.

Scope and Application

The Therapeutic Goods Act 1989 applies to entities involved in the manufacture, supply, and advertising of therapeutic goods within Australia. The Act encompasses a broad range of activities, including the production, importation, and distribution of therapeutic goods such as medicines, medical devices, and blood products. It applies to both individual persons and corporate entities that engage in these activities. The Act operates on a national level, covering all states and territories in Australia, with a mandate to ensure that therapeutic goods are safe, of high quality, and that their benefits outweigh any potential risks. The Act's provisions are enforced by the Therapeutic Goods Administration (TGA), which has the authority to issue licences, approve applications, and revoke licences as necessary to ensure compliance with the regulatory framework. However, certain activities and products may be exempt from the Act's requirements, including those explicitly listed in the legislation or those covered under specific exemptions or exclusions, such as goods for personal use. Additionally, the scope and application of the Act can be extended or restricted through subordinate instruments such as regulations or guidelines issued by the TGA.

Key Provisions

The Therapeutic Goods Act 1989 provides mechanisms for the regulation and oversight of therapeutic goods, including medications and medical devices, within Australia. In this context, section 41(1)(d) of the Act allows the Secretary to revoke a licence for the manufacture of therapeutic goods under specific circumstances. Pursuant to this provision, the Secretary has revoked the licence of the NSW Department of Primary Industries, Environmental Laboratory, Licence No MI-27012005-LI-000403-1, Original Number 55167, located at 1243 Bruxner Highway, Wollongbar NSW 2047, at the request of the manufacturer. Entities holding a licence to manufacture therapeutic goods are subject to stringent regulatory requirements designed to ensure the safety, quality, and efficacy of the goods they produce. This includes adhering to Good Manufacturing Practice (GMP) standards, maintaining detailed records of manufacturing processes, and ensuring compliance with all relevant legislative provisions. The revocation of a licence signifies that the manufacturer no longer has the authorisation to produce and supply therapeutic goods, potentially due to non-compliance with these regulatory standards. Failure to comply with the provisions of the Therapeutic Goods Act 1989 can result in significant legal consequences. Offences under the Act can lead to both civil and criminal penalties. For instance, knowingly supplying therapeutic goods that do not meet the standards set by the Act can result in fines of up to $1,215,000 for a corporation and imprisonment for up to five years for an individual. Additionally, the Act provides for the possibility of court-ordered compensation for any harm caused by the supply of non-compliant goods. These stringent measures underscore the importance of adhering to the regulatory framework established by the Act to ensure public health and safety.